The inflammatory actions of coagulant and fibrinolytic proteases in disease

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Schuliga, Michael ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; FIBRIN DEGRADATION PRODUCT; FIBRINOLYTIC AGENT; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; BLOOD CLOTTING FACTOR 10; FIBRINOGEN D FRAGMENT; PEPTIDE HYDROLASE; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANTICOAGULANT THERAPY; ASTHMA; ATHEROSCLEROSIS; CELL MIGRATION; DIMERIZATION; DISEASE EXACERBATION; DRUG MECHANISM; FIBRINOLYSIS; FIBROBLAST; HUMAN; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MYOFIBROBLAST; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE FIBER; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CHEMISTRY; GENETICS; INFLAMMATION; PHYSIOLOGY; PROTEIN MULTIMERIZATION;

BLOOD COAGULATION; FACTOR X; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; INFLAMMATION; PEPTIDE HYDROLASES; PROTEIN MULTIMERIZATION; RECEPTOR, PAR-1; RECEPTORS, GROWTH FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84926670217     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/437695     Document Type: Review

References (122)

1. H. H. Versteeg, J. W. M. Heemskerk, M. Levi, and P. H. Reitsma, "New fundamentals in hemostasis, " Physiological Reviews, vol. 93, no. 1, pp. 327-358, 2013.
2. T. Tucker and S. Idell, "Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury, " Seminars in Thrombosis and Hemostasis, vol. 39, no. 4, pp. 373-381, 2013.
3. S. S. Wagers, R. J. Norton, L. M. Rinaldi, J. H. T. Bates, B. E. Sobel, and C. G. Irvin, "Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness, " Journal of Clinical Investigation, vol. 114, no. 1, pp. 104-111, 2004.
4. P. W. Noble, C. E. Barkauskas, and D. Jiang, "Pulmonaryfibrosis: patterns and perpetrators, "The Journal of Clinical Investigation, vol. 122, no. 8, pp. 2756-2762, 2012.
5. E. B. Smith, "Fibrinogen, fibrin and the arterial wall, " European Heart Journal, vol. 16, supplement A, pp. 11-15, 1995.
6. H. Raghu and M. J. Flick, "Targeting the coagulation factor fibrinogen for arthritis therapy, " Current Pharmaceutical Biotechnology, vol. 12, no. 9, pp. 1497-1506, 2011.
7. F. W. Schardt, B. Schmausser, and E. Bachmann, "Monoclonal antibodies for immunodetection of fibrin deposits on cancer cells, " Histology and Histopathology, vol. 28, no. 8, pp. 993-998, 2013.
8. L. M. Altrogge and D. Monard, "An assay for high-sensitivity detection of thrombin activity and determination of proteases activating or inactivating protease-activated receptors, " Analytical Biochemistry, vol. 277, no. 1, pp. 33-45, 2000.
9. G. Bhattacharjee, J. Ahamed, R. Pawlinski et al., "Factor Xa binding to annexin 2mediates signal transduction via proteaseactivated receptor 1, " Circulation Research, vol. 102, no. 4, pp. 457-464, 2008.
10. M. Majumdar, T. Tarui, B. Shi, N. Akakura, W. Ruf, and Y. Takada, "Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin α9β1, " Journal of Biological Chemistry, vol. 279, no. 36, pp. 37528-37534, 2004.
11. Y. Wei, J. A. Eble, Z. Wang, J. A. Kreidberg, and H. A. Chapman, "Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1, "Molecular Biology of the Cell, vol. 12, no. 10, pp. 2975-2986, 2001.
12. K. Hu, C. Wu, W. M. Mars, and Y. Liu, "Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling, " The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3821-3832, 2007.
13. V. O. Millien, W. Lu, J. Shaw et al., "Cleavage of fibrinogen by proteinases elicits allergic responses through toll-like receptor 4, " Science, vol. 341, no. 6147, pp. 792-796, 2013.
14. A. G. Stewart, Y. C. Xia, T. Harris, S. Royce, J. A. Hamilton, and M. Schuliga, "Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling, " British Journal of Pharmacology, vol. 170, no. 7, pp. 1421-1435, 2013.
15. B. N. Lambrecht and H. Hammad, "Asthma and coagulation, " The New England Journal ofMedicine, vol. 369, no. 20, pp. 1964-1966, 2013.
16. J. D. de Boer, C. J. Majoor, C. Van't Veer, E. H. D. Bel, and T. van der Poll, "Asthma and coagulation, " Blood, vol. 119, no. 14, pp. 3236-3244, 2012.
17. R. A. Campbell, K. A. Overmyer, C. H. Selzman, B. C. Sheridan, and A. S. Wolberg, "Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability, " Blood, vol. 114, no. 23, pp. 4886-4896, 2009.
18. H. F. Dvorak, D. R. Senger, A. M. Dvorak, V. S. Harvey, and J. McDonagh, "Regulation of extravascular coagulation by microvascular permeability, " Science, vol. 227, no. 4690, pp. 1059-1061, 1985.
19. F. J. H. Brims, A. J. Chauhan, B. Higgins, and J. K. Shute, "Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids, " Thorax, vol. 64, no. 12, pp. 1037-1043, 2009.
20. A. Günther, P. Mosavi, C. Ruppert et al., "Enhancedtissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease, " Thrombosis and Haemostasis, vol. 83, no. 6, pp. 853-860, 2000.
21. C. J. Majoor, M. A. van de Pol, P. W. Kamphuisen et al., "Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study, " Respiratory Research, vol. 15, article 14, 2014.
22. C. J. Scotton, M. A. Krupiczojc, M. Königshoff et al., "Increased local expression of coagulation factor X contributes to the fibrotic response in human andmurine lung injury, "TheJournal of Clinical Investigation, vol. 119, no. 9, pp. 2550-2563, 2009.
23. F. Carmassi, F. de Negri, M. Morale, K. Y. Song, and S. I. Chung, "Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis, " Seminars in Thrombosis and Hemostasis, vol. 22, no. 6, pp. 489-496, 1996.
24. N. N. Jarjour and G. Enhorning, "Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant, " The American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 1, pp. 336-341, 1999.
25. S. Wagers, L. K. A. Lundblad, M. Ekman, C. G. Irvin, and J. H. T. Bates, "The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?" Journal of Applied Physiology, vol. 96, no. 6, pp. 2019-2027, 2004.
26. O. Sanchez-Pernaute, M. Filkova, A. Gabucio et al., "Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts, " Annals of the Rheumatic Diseases, vol. 72, no. 8, pp. 1400-1406, 2013.
27. J. Kim and K. A. Hajjar, "Annexin II: a plasminogenplasminogen activator co-receptor, " Frontiers in Bioscience, vol. 7, pp. d341-d348, 2002.
28. P. A. Madureira, A. P. Surette, K. D. Phipps, M. A. S. Taboski, V. A. Miller, and D. M. Waisman, "The role of the annexin A2 heterotetramer in vascular fibrinolysis, " Blood, vol. 118, no. 18, pp. 4789-4797, 2011.
29. H. C. Kwaan and B. McMahon, "The role of plasminogenplasmin system in cancer, " Cancer Treatment and Research, vol. 148, pp. 43-66, 2009.
30. M. Del Rosso, F. Margheri, S. Serratì, A. Chillà, A. Laurenzana, and G. Fibbi, "The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation, " Current Pharmaceutical Design, vol. 17, no. 19, pp. 1924-1943, 2011.
31. C. M. Swaisgood, E. L. French, C. Noga, R. H. Simon, and V. A. Ploplis, "The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system, " The American Journal of Pathology, vol. 157, no. 1, pp. 177-187, 2000.
32. C. E. Stewart, H. S. Nijmeh, C. E. Brightling, and I. Sayers, "uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium, " Thorax, vol. 67, no. 6, pp. 477-487, 2012.
33. M. Schuliga, S. Langenbach, Y. C. Xia et al., "Plasminogenstimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2, " The American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 5, pp. 751-758, 2013.
34. Q. Li, Y. Laumonnier, T. Syrovets, and T. Simmet, "Plasmin triggers cytokine induction in human monocyte-derived macrophages, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1383-1389, 2007.
35. W. P. Fay, N. Garg, and M. Sunkar, "Vascular functions of the plasminogen activation system, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1231-1237, 2007.
36. E. G. Levin and D. J. Loskutoff, "Comparative studies of the fibrinolytic activity of cultured vascular cells, " Thrombosis Research, vol. 15, no. 5-6, pp. 869-878, 1979.
37. B. J. Bloom, A. J. Alario, and L. C. Miller, "Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis, " Journal of Rheumatology, vol. 36, no. 2, pp. 422-426, 2009.
38. J. B. Weinberg, A. M. M. Pippen, and C. S. Greenberg, "Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis, " Arthritis and Rheumatism, vol. 34, no. 8, pp. 996-1005, 1991.
39. D. Yang and C. Y. Kuan, "Anti-tissue Plasminogen Activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation, " CNS Neuroscience and Therapeutics, 2014.
40. R. C. Chambers and C. J. Scotton, "Coagulation cascade proteinases in lung injury and fibrosis, " Proceedings of the American Thoracic Society, vol. 9, no. 3, pp. 96-101, 2012.
41. S. Shetty, A. Kumar, A. R. Johnson et al., "Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs, " The American Journal of Respiratory Cell and Molecular Biology, vol. 15, no. 1, pp. 78-87, 1996.
42. M. A. Olman, N. Mackman, C. L. Gladson, K. M. Moser, and D. J. Loskutoff, "Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse, " The Journal of Clinical Investigation, vol. 96, no. 3, pp. 1621-1630, 1995.
43. T. Nishiuma, T. H. Sisson, N. Subbotina, and R. H. Simon, "Localization of plasminogen activator activity within normal and injured lungs by in situ zymography, " The American Journal of Respiratory Cell andMolecular Biology, vol. 31, no. 5, pp. 552-558, 2004.
44. L. Tjeldhorn, P. M. Sandset, K. Haugbro, and G. Skretting, "Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis, " Thrombosis Research, vol. 125, no. 3, pp. 230-234, 2010.
45. F. J. H. Brims, A. J. Chauhan, B. Higgins, and J. K. Shute, "Up-regulation of the extrinsic coagulation pathway in acute asthma-a case Study, " Journal of Asthma, vol. 47, no. 6, pp. 695-698, 2010.
46. K. Kowal, S. Zukowski, M. Moniuszko, and A. Bodzentaukaszyk, "Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients, " Folia Histochemica et Cytobiologica, vol. 46, no. 2, pp. 193-198, 2008.
47. Z. Ma, D. Paek, and C. K. Oh, "Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation, " Clinical and Experimental Allergy, vol. 39, no. 8, pp. 1136-1144, 2009.
48. W. Xiao, Y.-P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss, "Sputumcathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation, " Chest, vol. 128, no. 4, pp. 2316-2326, 2005.
49. T. Iwaki, T. Urano, and K. Umemura, "PAI-1, progress in understanding the clinical problem and its aetiology, " British Journal of Haematology, vol. 157, no. 3, pp. 291-298, 2012.
50. M. Schneider and M. Nesheim, "A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis, " The Journal of Biological Chemistry, vol. 279, no. 14, pp. 13333-13339, 2004.
51. A. Tripodi and P. M. Mannucci, "The coagulopathy of chronic liver disease, "The New England Journal ofMedicine, vol. 365, no. 2, pp. 147-156, 2011.
52. D. A. Tregouet, R. Schnabel, M. C. Alessi et al., "Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study, " Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 49-57, 2009.
53. S. Saibeni, B. Bottasso, L. Spina et al., "Assessment of thrombinactivatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases, "The American Journal of Gastroenterology, vol. 99, no. 10, pp. 1966-1970, 2004.
54. E. L. G. Pryzdial and G. E. Kessler, "Autoproteolysis or plasminmediated cleavage of factor Xaα exposes a plasminogen binding site and inhibits coagulation, "The Journal of Biological Chemistry, vol. 271, no. 28, pp. 16614-16620, 1996.
55. K. Talbot, S. C. Meixner, and E. L. G. Pryzdial, "Enhanced fibrinolysis by proteolysed coagulation factor Xa, " Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1804, no. 4, pp. 723-730, 2010.
56. M. Åberg, M. Johnell, M. Wickström, and A. Siegbahn, "Tissue Factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1), " Thrombosis Research, vol. 127, no. 2, pp. 141-148, 2011.
57. S. J. Bolton, C. A. McNulty, R. J. Thomas, C. R. A. Hewitt, and A. J. Wardlaw, "Expression of and functional responses to protease-activated receptors on human eosinophils, " Journal of Leukocyte Biology, vol. 74, no. 1, pp. 60-68, 2003.
58. G. R. Stenton, O. Nohara, R. E. Déry et al., "Proteinase-activated receptor (PAR)-1 and-2 agonists induce mediator release from mast cells by pathways distinct fromPAR-1 and PAR-2, " Journal of Pharmacology and ExperimentalTherapeutics, vol. 302, no. 2, pp. 466-474, 2002.
59. W. Zhu, M. Bi, Y. Liu et al., "Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats, " Inhalation Toxicology, vol. 25, no. 10, pp. 577-586, 2013.
60. R. Colognato, J. R. Slupsky, M. Jendrach, L. Burysek, T. Syrovets, and T. Simmet, "Differential expression and regulation of protease-activated receptors in human peripheral monocytes andmonocyte-derived antigen-presenting cells, " Blood, vol. 102, no. 7, pp. 2645-2652, 2003.
61. D. A. Knight, S. Lim, A. K. Scaffidi et al., "Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma, " Journal of Allergy and Clinical Immunology, vol. 108, no. 5, pp. 797-803, 2001.
62. P. F. Mercer, R. H. Johns, C. J. Scotton et al., "Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary Fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 5, pp. 414-425, 2009.
63. D. C. J. Howell, R. H. Johns, J. A. Lasky et al., "Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis, " The American Journal of Pathology, vol. 166, no. 5, pp. 1353-1365, 2005.
64. A. Ortiz-Stern, X. Deng, N. Smoktunowicz, P. F. Mercer, and R. C. Chambers, "PAR-1-dependent and PAR-independent proinflammatory signaling in human lung fibroblasts exposed to thrombin, " Journal of Cellular Physiology, vol. 227, no. 11, pp. 3575-3584, 2012.
65. O. P. Blanc-Brude, F. Archer, P. Leoni et al., "FactorXa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation, " Experimental Cell Research, vol. 304, no. 1, pp. 16-27, 2005.
66. U. R. Pendurthi, M. Ngyuen, P. Andrade-Gordon, L. C. Petersen, and L. V. M. Rao, "Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 9, pp. 1421-1426, 2002.
67. L. Martorell, J. Martínez-González, C. Rodríguez, M. Gentile, O. Calvayrac, and L. Badimon, "Thrombin and proteaseactivated receptors (PARs) in atherothrombosis, " Thrombosis and Haemostasis, vol. 99, no. 2, pp. 305-315, 2008.
68. R. Kaufmann, S. Rahn, K. Pollrich et al., "Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4, " Journal of Cellular Physiology, vol. 211, no. 3, pp. 699-707, 2007.
69. M. Xue, Y.-K. A. Chan, K. Shen et al., "Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 64, no. 1, pp. 88-98, 2012.
70. E. Kerschen, I. Hernandez, M. Zogg et al., "Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice, "The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3167-3178, 2010.
71. C. Cao, Y. Gao, Y. Li, T. M. Antalis, F. J. Castellino, and L. Zhang, "The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b, " The Journal of Clinical Investigation, vol. 120, no. 6, pp. 1971-1980, 2010.
72. Y. Laumonnier, T. Syrovets, L. Burysek, and T. Simmet, "Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes, " Blood, vol. 107, no. 8, pp. 3342-3349, 2006.
73. T. J. MacLeod, M. Kwon, N. R. Filipenko, and D. M. Waisman, "Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits. Characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin, " The Journal of Biological Chemistry, vol. 278, no. 28, pp. 25577-25584, 2003.
74. L. Lin, C. Wu, and K. Hu, "Tissue plasminogen activator activates NF-kappaB through a pathway involving annexin A2/CD11b and integrin-linked kinase, " Journal of the American Society of Nephrology, vol. 23, no. 8, pp. 1329-1338, 2012.
75. H. Lin, A. P. Liu, T. H. Smith, and J. Trejo, "Cofactoring and dimerization of proteinase-activated receptors, " Pharmacological Reviews, vol. 65, no. 4, pp. 1198-1213, 2013.
76. T. A. McEachron, R. Pawlinski, K. L. Richards, F. C. Church, and N. Mackman, "Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis, " Blood, vol. 116, no. 23, pp. 5037-5044, 2010.
77. A. Coutts, G. Chen, N. Stephens et al., "Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 280, no. 5, pp. L999-L1008, 2001.
78. E. Roztocil, S. M. Nicholl, I. I. Galaria, and M. G. Davies, "Plasmin-induced smooth muscle cell proliferation requires epidermal growth factor activation through an extracellular pathway, " Surgery, vol. 138, no. 2, pp. 180-186, 2005.
79. E. I. Deryugina and J. P. Quigley, "Cell surface remodeling by plasmin: a new function for an old enzyme, " Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 564259, 21 pages, 2012.
80. M. Schuliga, T. Harris, and A. G. Stewart, "Plasminogen activation by airway smooth muscle is regulated by type I collagen, " The American Journal of Respiratory Cell andMolecular Biology, vol. 44, no. 6, pp. 831-839, 2011.
81. K. M. Austin, L. Covic, and A. Kuliopulos, "Matrix metalloproteases and PAR1 activation, " Blood, vol. 121, no. 3, pp. 431-439, 2013.
82. S. Shetty, Y. P. Bhandary, S. K. Shetty et al., "Induction of tissue factor by urokinase in lung epithelial cells and in the lungs, " American Journal of Respiratory and Critical CareMedicine, vol. 181, no. 12, pp. 1355-1366, 2010.
83. Y. Zhang, W. Xiao, Y. Jiang et al., "Levels of components of the urokinase-type plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling, " Journal of International Medical Research, vol. 40, no. 3, pp. 976-985, 2012.
84. A. D. Cook, C. M. De Nardo, E. L. Braine et al., "Urokinasetype plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement, " Arthritis Research andTherapy, vol. 12, no. 2, article R37, 2010.
85. L. Tang and X. Han, "The urokinase plasminogen activator system in breast cancer invasion and metastasis, " Biomedicine and Pharmacotherapy, vol. 67, no. 2, pp. 179-182, 2013.
86. A. de Paulis, N. Montuori, N. Prevete et al., "Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and-like 2, "TheJournal of Immunology, vol. 173, no. 9, pp. 5739-5748, 2004.
87. A. M. Bakken, C. D. Protack, E. Roztocil, S. M. Nicholl, and M. G. Davies, "Cell migration in response to the aminoterminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediatedmechanism, " Journal of Vascular Surgery, vol. 49, no. 5, pp. 1296-1303, 2009.
88. H. W. Smith and C. J. Marshall, "Regulation of cell signalling by uPAR, " Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 23-36, 2010.
89. T. Tarui, N. Akakura, M. Majumdar et al., "Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation, " Thrombosis and Haemostasis, vol. 95, no. 3, pp. 524-534, 2006.
90. R. M. Senior, W. F. Skogen, G. L. Griffin, and G. D. Wilner, "Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B, " The Journal of Clinical Investigation, vol. 77, no. 3, pp. 1014-1019, 1986.
91. D. L. Richardson, D. S. Pepper, and A. B. Kay, "Chemotaxis for human monocytes by fibrinogen derived peptides, " British Journal of Haematology, vol. 32, no. 4, pp. 507-513, 1976.
92. T. J. Gross, K. J. Leavell, and M. W. Peterson, "CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain, " Thrombosis and Haemostasis, vol. 77, no. 5, pp. 894-900, 1997.
93. M. Naito, C. M. Stirk, E. B. Smith, and W. D. Thompson, "Smooth muscle cell outgrowth stimulated by fibrin degradation products: the potential role of fibrin fragment E in restenosis and atherogenesis, " Thrombosis Research, vol. 98, no. 2, pp. 165-174, 2000.
94. S. C. Robson, E. G. Shephard, and R. E. Kirsch, "Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro, " British Journal of Haematology, vol. 86, no. 2, pp. 322-326, 1994.
95. M. Hamaguchi, Y. Morishita, I. Takahashi, M. Ogura, J. Takamatsu, and H. Saito, "FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line, " Blood, vol. 77, no. 1, pp. 94-100, 1991.
96. C. Jennewein, N. Tran, P. Paulus, P. Ellinghaus, J. A. Eble, and K. Zacharowski, "Novel aspects of fibrin(ogen) fragments during inflammation, "MolecularMedicine, vol. 17, no. 5-6, pp. 568-573, 2011.
97. R. V. Lalla, M. L. Tanzer, and D. L. Kreutzer, "Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells, " Archives of Oral Biology, vol. 48, no. 4, pp. 263-271, 2003.
98. M. Gröger, W. Pasteiner, G. Ignatyev et al., "Peptide Bβ15-42 preserves endothelial barrier function in shock, " PLoSONE, vol. 4, no. 4, Article ID e5391, 2009.
99. J. P. Roesner, P. Petzelbauer, A. Koch et al., "Bβ15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion, " Critical Care Medicine, vol. 37, no. 2, pp. 598-605, 2009.
100. K. Doronin, J. W. Flatt, N. C. di Paolo et al., "Coagulation factor X activates innate immunity to human species C adenovirus, " Science, vol. 338, no. 6108, pp. 795-798, 2012.
101. J. F. A. Swisher, N. Burton, S. M. Bacot, S. N. Vogel, and G. M. Feldman, "Annexin A2 tetramer activates human and murine macrophages through TLR4, " Blood, vol. 115, no. 3, pp. 549-558, 2010.
102. K. L. Allen, F. V. Fonseca, V. Betapudi, B. Willard, J. Zhang, and K. R. McCrae, "A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies, " Blood, vol. 119, no. 3, pp. 884-893, 2012.
103. K.-L. He, G. Sui, H. Xiong et al., "Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2, " The Journal of Biological Chemistry, vol. 286, no. 17, pp. 15428-15439, 2011.
104. D. K. Ingawale, S. K. Mandlik, and S. S. Patel, "An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance, " Journal of Complementary and Integrative Medicine, vol. 12, no. 1, pp. 1-13, 2015.
105. C. R. Keenan, S. Salem, E. R. Fietz, R. C. Gualano, and A. G. Stewart, "Glucocorticoid-resistant asthma and novel antiinflammatory drugs, " Drug Discovery Today, vol. 17, no. 17-18, pp. 1031-1038, 2012.
106. T. Tran, D. J. Fernandes, M. Schuliga, T. Harris, L. Landells, and A. G. Stewart, "Stimulus-dependent glucocorticoid-resistance of GM-CSF production in human cultured airway smooth muscle, " British Journal of Pharmacology, vol. 145, no. 1, pp. 123-131, 2005.
107. J. V. Bonacci, M. Schuliga, T. Harris, and A. G. Stewart, "Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signalling, " British Journal of Pharmacology, vol. 149, no. 4, pp. 365-373, 2006.
108. Y. Xie, K. Gao, L. Häkkinen, and H. S. Larjava, "Mice lacking β6 integrin in skin show accelerated wound repair in dexamethasone impaired wound healing model, " Wound Repair and Regeneration, vol. 17, no. 3, pp. 326-339, 2009.
109. J. A. P. Spijkers-Hagelstein, S. M. Pinhanços, P. Schneider, R. Pieters, and R. W. Stam, "Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLLrearranged infant acute lymphoblastic leukemia, " Leukemia, vol. 27, no. 5, pp. 1063-1071, 2013.
110. J. Graff and S. Harder, "Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment, " Clinical Pharmacokinetics, vol. 52, no. 4, pp. 243-254, 2013.
111. S. L. French, J. F. Arthur, H. A. Tran, and J. R. Hamilton, "Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent, " Blood Reviews, 2014.
112. D. Capodanno, D. L. Bhatt, S. Goto et al., "Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials, " Journal ofThrombosis andHaemostasis, vol. 10, no. 10, pp. 2006-2015, 2012.
113. M. Zhu, V. M. Gokhale, L. Szabo et al., "Identification of a novel inhibitor of urokinase-type plasminogen activator, " Molecular CancerTherapeutics, vol. 6, no. 4, pp. 1348-1356, 2007.
114. I. Henneke, S. Greschus, R. Savai et al., "Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model, " The American Journal of Respiratory and Critical CareMedicine, vol. 181, no. 6, pp. 611-619, 2010.
115. M. Schmitt, N. Harbeck, N. Brünner et al., "Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1, " Expert Review of Molecular Diagnostics, vol. 11, no. 6, pp. 617-634, 2011.
116. I. K. Lund, M. G. Rasch, S. Ingvarsen et al., "Inhibitory monoclonal antibodies against mouse proteases raised inGene-Deficient mice block proteolytic functions in vivo, " Frontiers in Pharmacology, vol. 3, article 122, 2012.
117. K. A. Botkjaer, S. Fogh, E. C. Bekes et al., "Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies, " Biochemical Journal, vol. 438, no. 1, pp. 39-51, 2011.
118. X.-Q. Wang, K. Bdeir, S. Yarovoi, D. B. Cines, W. Fang, and E. Abraham, "Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury, " The Journal of Immunology, vol. 177, no. 8, pp. 5550-5557, 2006.
119. J. Inokuchi, N. Narula, D. S. Yee et al., "Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells, " International Journal of Cancer, vol. 124, no. 1, pp. 68-74, 2009.
120. M. R. Sharma, V. Rothman, G. P. Tuszynski, and M. C. Sharma, "Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action, " Experimental andMolecular Pathology, vol. 81, no. 2, pp. 136-145, 2006.
121. M. Sharma, M. R. Blackman, and M. C. Sharma, "Antibodydirected neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model, " Experimental andMolecular Pathology, vol. 92, no. 1, pp. 175-184, 2012.
122. L. Zheng and E. M. Jaffee, "Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy, " OncoImmunology, vol. 1, no. 1, pp. 112-114, 2012.